Antibody Solutions for DNA Methylation & Epigenetic Regulation Research

From DNA Modification Dynamics to Disease Mechanisms — Empowering Comprehensive Epigenetic Discovery with Validated Antibody Solutions

Epigenetic regulation plays a fundamental role in controlling genome organization, chromatin accessibility, transcriptional activity, cellular identity, development, aging, and disease progression. Among the major epigenetic mechanisms, DNA methylation and demethylation represent dynamic regulatory processes that shape gene expression programs through coordinated modification, interpretation, and remodeling of DNA methylation landscapes.

DNA methylation patterns are established and maintained through the coordinated activity of DNA methyltransferases (DNMTs), ten-eleven translocation (TET) enzymes, methyl-CpG binding proteins, and associated chromatin regulators. Alterations in these regulatory networks can lead to abnormal gene regulation and contribute to diverse biological and pathological processes, including:

• Cancer initiation, progression, and therapeutic resistance 
• Immune-cell differentiation and inflammatory regulation 
• Neurodevelopmental and neurodegenerative disorders 
• Stem cell maintenance and lineage specification 
• Aging-associated epigenomic remodeling 
• Disease-associated biomarker development 

We provide comprehensive antibody solutions for investigating DNA methylation biology—from epigenetic modification profiling and regulatory pathway analysis to disease-associated biomarker discovery. Validated antibodies enable researchers to characterize methylation writers, erasers, readers, and DNA modification states using Western blotting (WB), immunofluorescence (IF), immunohistochemistry (IHC), chromatin immunoprecipitation (ChIP), and multiplex imaging platforms.

By integrating high-quality antibody reagents with advanced epigenetic profiling approaches, researchers can decode complex regulatory networks, identify functional methylation signatures, and accelerate discoveries in cancer biology, neuroscience, immunology, developmental biology, stem cell research, and precision medicine.

DNA Methylation & Epigenetic Regulation Biomarker Antibody Portfolio

——Comprehensive Solutions for Epigenetic Modification Mapping, Regulatory Mechanism Analysis, and Disease Research

Understanding DNA methylation requires systematic analysis of the complete epigenetic regulatory network, including enzymes responsible for writing, erasing, maintaining, and interpreting DNA methylation signals.

Our antibody portfolio provides validated research tools targeting key components of DNA methylation regulation:

Featured DNA Methylation Research Panels

——Comprehensive Antibody Panels for Epigenetic Profiling and Mechanistic Discovery

DNA methylation is a dynamic layer of epigenetic regulation that controls chromatin accessibility, transcriptional activity, genomic stability, and cell identity. Its establishment, maintenance, and active remodeling are coordinated by DNA methyltransferases, TET-mediated oxidation pathways, methyl-DNA binding proteins, and chromatin regulatory complexes. Our integrated antibody panels enable researchers to move from DNA methylation machinery and modified DNA states to chromatin regulation and disease-associated epigenetic remodeling.

• DNA Methylation Regulation Panel—Defining DNA Methylation Establishment and Maintenance Mechanisms

Key Markers

• DNA Demethylation Panel—Characterizing Active DNA Demethylation and Epigenetic Remodeling

Key Markers

• Neuroepigenetics Panel—Decoding DNA Methylation Regulation in Neural Biology

Key Markers

• Cancer Epigenetics Panel—Investigating Aberrant DNA Methylation in Tumor Biology

Key Markers

Why Researchers Choose Our DNA Methylation Antibody Solutions

Validated Targets. Comprehensive Panels. Reliable Epigenetic Research.

Our antibody portfolio supports the complete DNA methylation research workflow—from epigenetic profiling and pathway investigation to disease-associated biomarker discovery.

Key References

1. López-Moyado IF, Ko M, Hogan PG, Rao A. TET Enzymes in the Immune System: From DNA Demethylation to Immunotherapy, Inflammation, and Cancer. Annu Rev Immunol. 2024 Jun;42(1):455-488.

2. Shi J, Xu J, Chen YE, Li JS, Cui Y, Shen L, Li JJ, Li W. The concurrence of DNA methylation and demethylation is associated with transcription regulation. Nat Commun. 2021 Sep 6;12(1):5285.

3. Yamada Y, Venkadakrishnan VB, Mizuno K, Bakht M, Ku SY, Garcia MM, Beltran H. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer. Sci Transl Med. 2023 Nov 15;15(722):eadf6732.

4. Bender A, Morel M, Dumas M, Klopfenstein M, Osmani N, Greenberg MVC, Bourc'his D, Ghyselinck NB, Weber M. UHRF2 mediates resistance to DNA methylation reprogramming in primordial germ cells. Nat Commun. 2025 Aug 9;16(1):7350.

5. Lea G, Doria-Borrell P, Ferrero-Micó A, Varma A, Simon C, Anderson H, Biggins L, De Clercq K, Andrews S, Niakan KK, Gahurova L, McGovern N, Pérez-García V, Hanna CW. Ectopic expression of DNMT3L in human trophoblast stem cells restores features of the placental methylome. Cell Stem Cell. 2025 Feb 6;32(2):276-292.e9.

6. Xavier Raj I, Kyun Koh W, Harrison J, Zhang CR, Soares B, Amato R, Krishnan A, O'Leary DR, Bjeije H, Parsons TM, Han W, Young AL, Wang T, Batista LFZ, Challen GA. Non-canonical functions of DNMT3A in hematopoietic stem cells regulate telomerase activity and genome integrity. Cell Stem Cell. 2025 Aug 7;32(8):1251-1266.e8.

7. Greenberg MVC, Bourc'his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019 Oct;20(10):590-607.